The Economic Evaluation of Precision Medicine in Diabetes: Models and Approaches

Standard economic evaluations, including cost-effectiveness and cost-utility studies present outcomes at the population level. Novel precision medicine strategies may ask for tailored approaches that use existing simulation models in a novel way, or even require adjustment of these simulation models. In the talk different examples of evaluations of precision medicine in Diabetes will be presented and discussed with the audience to gain insight into the possibilities and pitfalls of evaluating precision medicine interventions.

Learning objectives: Insight into approaches to evaluating prediction model-based treatment strategies in Diabetes; Compare supervised (prediction models) and unsupervised learning (K-means clustering) options as a way towards tailored treatment and gain insight into what we still need to know for full insight into their economic value.

Papers that will be discussed are:

A personalized screening strategy for diabetic retinopathy: a cost-effectiveness perspective
(https://link.springer.com/article/10.1007/s00125-020-05239-9) and

Potential Value of Identifying Type 2 Diabetes Subgroups for Guiding Intensive Treatment: A Comparison of Novel Data-Driven Clustering With Risk-Driven Subgroups. (https://diabetesjournals.org/care/article/46/7/1395/148825/Potential-Value-of-Identifying-Type-2-Diabetes)